Incidence, Risk Factors, and Outcome of Cytomegalovirus Infection and Disease in Patients Receiving Prophylaxis with Oral Valganciclovir or Intravenous Ganciclovir after Umbilical Cord Blood Transplantation

Pau Montesinos, Jaime Sanz, Susana Cantero Peral, Ignacio Lorenzo, Guillermo Martín, Silvana Saavedra, Javier Palau, Mónica Romero, Alberto Montava, Leonor Senent, Jesús Martínez, Isidro Jarque, Miguel Salavert, Juan Córdoba, Lola Gómez, Shirley Weiss, Federico Moscardó, Javier de la Rubia, Luis Larrea, Miguel A. SanzGuillermo F. Sanz

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

There is no information on the efficacy and safety of anticytomegalovirus (CMV) prophylaxis with intravenous ganciclovir or oral valganciclovir after unrelated cord-blood transplantation (UCBT). This issue was addressed in 151 adults (117 CMV-seropositive) undergoing UCBT at a single institution. The first 38 CMV-seropositive recipients were assigned to receive prophylactic ganciclovir, and the next 79 were given valganciclovir after engraftment. The cumulative incidence (CI) of CMV infection and disease was similar in patients receiving valganciclovir or ganciclovir (59% versus 55%, P = .59; and 9% versus 18%, P = .33, respectively). The toxicity profile and CI of nonrelapse mortality (CMV) and infection-related mortality did not differ between drugs. Patients receiving valganciclovir required fewer visits to the day hospital (P = .04). The CI of CMV infection and disease in 34 CMV-seronegative recipients was 12% and 6%, indicating that tight CMV monitoring is mandatory in this subset. The recipient's CMV serostatus, acute and extensive chronic graft-versus-host disease (aGVHD, cGVHD) were the main risk factors for CMV infection, and aGVHD for CMV disease. This study suggests that prophylaxis with oral valganciclovir is as safe and effective as intravenous ganciclovir for preventing CMV infection and disease after UCBT, but valganciclovir reduces the use of hospital resources.

Original languageEnglish (US)
Pages (from-to)730-740
Number of pages11
JournalBiology of Blood and Marrow Transplantation
Volume15
Issue number6
DOIs
StatePublished - Jun 1 2009
Externally publishedYes

Fingerprint

Ganciclovir
Cytomegalovirus Infections
Fetal Blood
Transplantation
Incidence
Infection
Mortality
Graft vs Host Disease
valganciclovir
Safety
Pharmaceutical Preparations

Keywords

  • Cytomegalovirus
  • Ganciclovir
  • Prophylaxis
  • Umbilical cord blood transplantation
  • Valganciclovir

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Incidence, Risk Factors, and Outcome of Cytomegalovirus Infection and Disease in Patients Receiving Prophylaxis with Oral Valganciclovir or Intravenous Ganciclovir after Umbilical Cord Blood Transplantation. / Montesinos, Pau; Sanz, Jaime; Cantero Peral, Susana; Lorenzo, Ignacio; Martín, Guillermo; Saavedra, Silvana; Palau, Javier; Romero, Mónica; Montava, Alberto; Senent, Leonor; Martínez, Jesús; Jarque, Isidro; Salavert, Miguel; Córdoba, Juan; Gómez, Lola; Weiss, Shirley; Moscardó, Federico; de la Rubia, Javier; Larrea, Luis; Sanz, Miguel A.; Sanz, Guillermo F.

In: Biology of Blood and Marrow Transplantation, Vol. 15, No. 6, 01.06.2009, p. 730-740.

Research output: Contribution to journalArticle

Montesinos, P, Sanz, J, Cantero Peral, S, Lorenzo, I, Martín, G, Saavedra, S, Palau, J, Romero, M, Montava, A, Senent, L, Martínez, J, Jarque, I, Salavert, M, Córdoba, J, Gómez, L, Weiss, S, Moscardó, F, de la Rubia, J, Larrea, L, Sanz, MA & Sanz, GF 2009, 'Incidence, Risk Factors, and Outcome of Cytomegalovirus Infection and Disease in Patients Receiving Prophylaxis with Oral Valganciclovir or Intravenous Ganciclovir after Umbilical Cord Blood Transplantation', Biology of Blood and Marrow Transplantation, vol. 15, no. 6, pp. 730-740. https://doi.org/10.1016/j.bbmt.2009.03.002
Montesinos, Pau ; Sanz, Jaime ; Cantero Peral, Susana ; Lorenzo, Ignacio ; Martín, Guillermo ; Saavedra, Silvana ; Palau, Javier ; Romero, Mónica ; Montava, Alberto ; Senent, Leonor ; Martínez, Jesús ; Jarque, Isidro ; Salavert, Miguel ; Córdoba, Juan ; Gómez, Lola ; Weiss, Shirley ; Moscardó, Federico ; de la Rubia, Javier ; Larrea, Luis ; Sanz, Miguel A. ; Sanz, Guillermo F. / Incidence, Risk Factors, and Outcome of Cytomegalovirus Infection and Disease in Patients Receiving Prophylaxis with Oral Valganciclovir or Intravenous Ganciclovir after Umbilical Cord Blood Transplantation. In: Biology of Blood and Marrow Transplantation. 2009 ; Vol. 15, No. 6. pp. 730-740.
@article{7265e7870a764ac39f41d98fc17e2eff,
title = "Incidence, Risk Factors, and Outcome of Cytomegalovirus Infection and Disease in Patients Receiving Prophylaxis with Oral Valganciclovir or Intravenous Ganciclovir after Umbilical Cord Blood Transplantation",
abstract = "There is no information on the efficacy and safety of anticytomegalovirus (CMV) prophylaxis with intravenous ganciclovir or oral valganciclovir after unrelated cord-blood transplantation (UCBT). This issue was addressed in 151 adults (117 CMV-seropositive) undergoing UCBT at a single institution. The first 38 CMV-seropositive recipients were assigned to receive prophylactic ganciclovir, and the next 79 were given valganciclovir after engraftment. The cumulative incidence (CI) of CMV infection and disease was similar in patients receiving valganciclovir or ganciclovir (59{\%} versus 55{\%}, P = .59; and 9{\%} versus 18{\%}, P = .33, respectively). The toxicity profile and CI of nonrelapse mortality (CMV) and infection-related mortality did not differ between drugs. Patients receiving valganciclovir required fewer visits to the day hospital (P = .04). The CI of CMV infection and disease in 34 CMV-seronegative recipients was 12{\%} and 6{\%}, indicating that tight CMV monitoring is mandatory in this subset. The recipient's CMV serostatus, acute and extensive chronic graft-versus-host disease (aGVHD, cGVHD) were the main risk factors for CMV infection, and aGVHD for CMV disease. This study suggests that prophylaxis with oral valganciclovir is as safe and effective as intravenous ganciclovir for preventing CMV infection and disease after UCBT, but valganciclovir reduces the use of hospital resources.",
keywords = "Cytomegalovirus, Ganciclovir, Prophylaxis, Umbilical cord blood transplantation, Valganciclovir",
author = "Pau Montesinos and Jaime Sanz and {Cantero Peral}, Susana and Ignacio Lorenzo and Guillermo Mart{\'i}n and Silvana Saavedra and Javier Palau and M{\'o}nica Romero and Alberto Montava and Leonor Senent and Jes{\'u}s Mart{\'i}nez and Isidro Jarque and Miguel Salavert and Juan C{\'o}rdoba and Lola G{\'o}mez and Shirley Weiss and Federico Moscard{\'o} and {de la Rubia}, Javier and Luis Larrea and Sanz, {Miguel A.} and Sanz, {Guillermo F.}",
year = "2009",
month = "6",
day = "1",
doi = "10.1016/j.bbmt.2009.03.002",
language = "English (US)",
volume = "15",
pages = "730--740",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Incidence, Risk Factors, and Outcome of Cytomegalovirus Infection and Disease in Patients Receiving Prophylaxis with Oral Valganciclovir or Intravenous Ganciclovir after Umbilical Cord Blood Transplantation

AU - Montesinos, Pau

AU - Sanz, Jaime

AU - Cantero Peral, Susana

AU - Lorenzo, Ignacio

AU - Martín, Guillermo

AU - Saavedra, Silvana

AU - Palau, Javier

AU - Romero, Mónica

AU - Montava, Alberto

AU - Senent, Leonor

AU - Martínez, Jesús

AU - Jarque, Isidro

AU - Salavert, Miguel

AU - Córdoba, Juan

AU - Gómez, Lola

AU - Weiss, Shirley

AU - Moscardó, Federico

AU - de la Rubia, Javier

AU - Larrea, Luis

AU - Sanz, Miguel A.

AU - Sanz, Guillermo F.

PY - 2009/6/1

Y1 - 2009/6/1

N2 - There is no information on the efficacy and safety of anticytomegalovirus (CMV) prophylaxis with intravenous ganciclovir or oral valganciclovir after unrelated cord-blood transplantation (UCBT). This issue was addressed in 151 adults (117 CMV-seropositive) undergoing UCBT at a single institution. The first 38 CMV-seropositive recipients were assigned to receive prophylactic ganciclovir, and the next 79 were given valganciclovir after engraftment. The cumulative incidence (CI) of CMV infection and disease was similar in patients receiving valganciclovir or ganciclovir (59% versus 55%, P = .59; and 9% versus 18%, P = .33, respectively). The toxicity profile and CI of nonrelapse mortality (CMV) and infection-related mortality did not differ between drugs. Patients receiving valganciclovir required fewer visits to the day hospital (P = .04). The CI of CMV infection and disease in 34 CMV-seronegative recipients was 12% and 6%, indicating that tight CMV monitoring is mandatory in this subset. The recipient's CMV serostatus, acute and extensive chronic graft-versus-host disease (aGVHD, cGVHD) were the main risk factors for CMV infection, and aGVHD for CMV disease. This study suggests that prophylaxis with oral valganciclovir is as safe and effective as intravenous ganciclovir for preventing CMV infection and disease after UCBT, but valganciclovir reduces the use of hospital resources.

AB - There is no information on the efficacy and safety of anticytomegalovirus (CMV) prophylaxis with intravenous ganciclovir or oral valganciclovir after unrelated cord-blood transplantation (UCBT). This issue was addressed in 151 adults (117 CMV-seropositive) undergoing UCBT at a single institution. The first 38 CMV-seropositive recipients were assigned to receive prophylactic ganciclovir, and the next 79 were given valganciclovir after engraftment. The cumulative incidence (CI) of CMV infection and disease was similar in patients receiving valganciclovir or ganciclovir (59% versus 55%, P = .59; and 9% versus 18%, P = .33, respectively). The toxicity profile and CI of nonrelapse mortality (CMV) and infection-related mortality did not differ between drugs. Patients receiving valganciclovir required fewer visits to the day hospital (P = .04). The CI of CMV infection and disease in 34 CMV-seronegative recipients was 12% and 6%, indicating that tight CMV monitoring is mandatory in this subset. The recipient's CMV serostatus, acute and extensive chronic graft-versus-host disease (aGVHD, cGVHD) were the main risk factors for CMV infection, and aGVHD for CMV disease. This study suggests that prophylaxis with oral valganciclovir is as safe and effective as intravenous ganciclovir for preventing CMV infection and disease after UCBT, but valganciclovir reduces the use of hospital resources.

KW - Cytomegalovirus

KW - Ganciclovir

KW - Prophylaxis

KW - Umbilical cord blood transplantation

KW - Valganciclovir

UR - http://www.scopus.com/inward/record.url?scp=67349276054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349276054&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2009.03.002

DO - 10.1016/j.bbmt.2009.03.002

M3 - Article

C2 - 19450758

AN - SCOPUS:67349276054

VL - 15

SP - 730

EP - 740

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 6

ER -